Topical Ruxolitinib Therapeutic Cheat Sheet
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … Continue reading "Topical Ruxolitinib Therapeutic Cheat Sheet"
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o … 
Dr. Lawrence F. Eichenfield, meeting co-chair for the 17th Annual Women’s and Pediatric Dermatology Seminar, kicked off session III with a superb talk titled “Scaling the Heights…and Below, Pediatric Scaling Diseases: Psoriasis and Others”, giving us a bird’s eye view on the old and the new regarding pediatric psoriasis.
Dr. Eichenfield is a complete rock star and served as a valued … 
Millions of patients experience unwanted facial hair, severely impacting their quality of life. Laser hair removal is often the treatment of choice, but this therapy is uncomfortable, requires multiple treatments, and risks pigmentary changes. Therefore, an effective topical therapy for reduction of unwanted hair is a valuable addition to our therapeutic repertoire. We continue our series, Therape … 
Sprinkled with many clinical pearls, Dr. Candrice Heath gave us an informative, case-based lecture at the 2021 Skin of Color Update: “Skin Conditions Disproportionately Affecting Pediatric & Adolescent Patients with Skin of Color.” Dr. Heath is an Assistant Professor and Director of Pediatric Dermatology at Lewis Katz School of Medicine at Temple University and is active on social media @D …